Log in
NASDAQ:MIST

Milestone Pharmaceuticals Stock Forecast, Price & News

$8.63
+0.08 (+0.94 %)
(As of 09/17/2020 12:00 AM ET)
Add
Compare
Today's Range
$8.30
Now: $8.63
$8.74
50-Day Range
$7.71
MA: $8.33
$9.80
52-Week Range
$1.69
Now: $8.63
$23.25
Volume96,800 shs
Average Volume2.55 million shs
Market Capitalization$213.25 million
P/E RatioN/A
Dividend YieldN/A
Beta4.79
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina. The company was founded in 2003 and is headquartered in Montréal, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.40 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MIST
CUSIPN/A
CIKN/A
Phone514-336-0444

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.69 per share

Profitability

Net Income$-55,230,000.00

Miscellaneous

Employees20
Market Cap$213.25 million
Next Earnings Date11/11/2020 (Estimated)
OptionableNot Optionable
$8.63
+0.08 (+0.94 %)
(As of 09/17/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MIST News and Ratings via Email

Sign-up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Milestone Pharmaceuticals (NASDAQ:MIST) Frequently Asked Questions

How has Milestone Pharmaceuticals' stock price been impacted by COVID-19?

Milestone Pharmaceuticals' stock was trading at $19.99 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, MIST stock has decreased by 56.8% and is now trading at $8.63.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Milestone Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Milestone Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Milestone Pharmaceuticals
.

When is Milestone Pharmaceuticals' next earnings date?

Milestone Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Milestone Pharmaceuticals
.

How were Milestone Pharmaceuticals' earnings last quarter?

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) released its quarterly earnings results on Wednesday, August, 12th. The company reported ($0.53) EPS for the quarter, missing the Zacks' consensus estimate of ($0.51) by $0.02.
View Milestone Pharmaceuticals' earnings history
.

What price target have analysts set for MIST?

4 analysts have issued 12 month price objectives for Milestone Pharmaceuticals' shares. Their forecasts range from $8.00 to $18.00. On average, they expect Milestone Pharmaceuticals' stock price to reach $13.25 in the next twelve months. This suggests a possible upside of 53.5% from the stock's current price.
View analysts' price targets for Milestone Pharmaceuticals
.

Are investors shorting Milestone Pharmaceuticals?

Milestone Pharmaceuticals saw a drop in short interest in the month of August. As of August 14th, there was short interest totaling 1,290,000 shares, a drop of 15.1% from the July 30th total of 1,520,000 shares. Based on an average daily trading volume, of 5,390,000 shares, the short-interest ratio is presently 0.2 days. Approximately 10.4% of the shares of the company are sold short.
View Milestone Pharmaceuticals' Short Interest
.

Who are some of Milestone Pharmaceuticals' key competitors?

What other stocks do shareholders of Milestone Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Milestone Pharmaceuticals investors own include CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Ibio (IBIO), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), Menlo Therapeutics (MNLO), Opko Health (OPK), Soleno Therapeutics (SLNO) and Agile Therapeutics (AGRX).

Who are Milestone Pharmaceuticals' key executives?

Milestone Pharmaceuticals' management team includes the following people:
  • Mr. Joseph G. Oliveto, CEO, Pres & Director (Age 51)
  • Dr. Philippe Douville, Founder & Chief Scientific Officer (Age 57)
  • Mr. Timothy L. Maness, VP of Fin. (Age 59)
  • Dr. Francis Plat, Chief Medical Officer (Age 61)
  • Mr. Lorenz Muller, Chief Commercial Officer (Age 55)

When did Milestone Pharmaceuticals IPO?

(MIST) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Piper Jaffray served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Milestone Pharmaceuticals' stock symbol?

Milestone Pharmaceuticals trades on the NASDAQ under the ticker symbol "MIST."

Who are Milestone Pharmaceuticals' major shareholders?

Milestone Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include K2 Principal Fund L.P. (0.69%), Schonfeld Strategic Advisors LLC (0.13%), California Public Employees Retirement System (0.13%) and Two Sigma Advisers LP (0.08%). Company insiders that own Milestone Pharmaceuticals stock include De Solidarite Des Travai Fonds, Holdings A/S Novo, Rtw Investments, Lp and Stonepine Capital, LP.
View institutional ownership trends for Milestone Pharmaceuticals
.

Which institutional investors are buying Milestone Pharmaceuticals stock?

MIST stock was acquired by a variety of institutional investors in the last quarter, including K2 Principal Fund L.P., Schonfeld Strategic Advisors LLC, California Public Employees Retirement System, and Two Sigma Advisers LP. Company insiders that have bought Milestone Pharmaceuticals stock in the last two years include Holdings A/S Novo, Rtw Investments, Lp, and Stonepine Capital, LP.
View insider buying and selling activity for Milestone Pharmaceuticals
.

How do I buy shares of Milestone Pharmaceuticals?

Shares of MIST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Milestone Pharmaceuticals' stock price today?

One share of MIST stock can currently be purchased for approximately $8.63.

How big of a company is Milestone Pharmaceuticals?

Milestone Pharmaceuticals has a market capitalization of $213.25 million. The company earns $-55,230,000.00 in net income (profit) each year or ($3.50) on an earnings per share basis. Milestone Pharmaceuticals employs 20 workers across the globe.

What is Milestone Pharmaceuticals' official website?

The official website for Milestone Pharmaceuticals is www.milestonepharma.com.

How can I contact Milestone Pharmaceuticals?

Milestone Pharmaceuticals' mailing address is 1111 DR. FREDERIK-PHILIPS BLVD SUITE 420, MONTREAL A8, H4M 2X6. The company can be reached via phone at 514-336-0444 or via email at [email protected]

This page was last updated on 9/18/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.